NORAPP: Transperineal MRI-TRUS Fusion Guided Prostate Biopsy With vs Without Antibiotic Prophylaxis
Study Details
Study Description
Brief Summary
Prostate biopsy is indicated in patients with suspected prostate cancer and has been traditionally performed through the rectum using antibiotic prophylaxis. Increasing antibiotic resistance of intestinal bacteria is causing a growing number of patients to get post-biopsy infections. Sepsis rate after transrectal biopsies is approximately 4-10%.
To reduce the risk of post-biopsy infections, transperineal approach in general anesthesia and antibiotic prophylaxis has been used. The investigators at Oslo University Hospital Aker developed MRI -TURS elastic image fusion guided transperineal prostate biopsy technique in local anesthesia and Bactrim prophylaxis as outpatient procedure. The investigators found 0.4% post-biopsy infection rate. Afterwards a pilot study using the same biopsy technique however without antibiotic prophylaxis was realized in 90 patients. None of these subjects experienced infection.
The investigators wish to perform a prospective randomized trial of antibiotic prophylaxis versus none before transperineal MRI-TRUS fusion guided prostate biopsy in local anesthesia in outpatient clinic.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Background: Unnecessary use of antibiotics promotes antibiotic resistance. Efforts for antibiotic use reduction without increase the risk of serious infection complications are therefore needed.
Purpose: The aim of this trial is to compare the rates of infectious complication after transperineal prostate biopsy in patients with and without antibiotic prophylaxis.
Materials and methods: A total of 450 patients will be included in this trial. A 1:1 randomization to receive or not receive antibiotics prophylaxis will be performed using randomization system WebCRF-3 system. MRI-TRUS fusion prostate biopsy will be done with transperineal prostate approach in local anesthesia in outpatient clinic. In patients with normal MRI,12-core systematic prostate biopsies with 3D biopsy registration will be done according to the EAU guidelines. In patients with positive MRI, 2-4 targeted biopsies from the suspicious MRI areas will be realized and systematic prostate biopsies will also be done. All prostate biopsies will be performed using Koelis MRI-TRUS image fusion and organ based tracking system. Post-biopsy infection and any adverse events will be systematically prospectively registered in all patients. Pain during the local anesthesia application and during the biopsy procedure will be registered using Visual Analog Score, 10 points scale questionnaire.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Transperineal prostate biopsy with antibiotic profylaxis Cefuroxim 1.5 g will be applied intramuscularly before prostate biopsy |
Procedure: Transperineal prostate biopsy with or without antibiotic prophylaxis
As described above.
|
| Experimental: Transperineal prostate biopsy without antibiotic profylaxis No antibiotics will be used before or after prostate biopsy |
Procedure: Transperineal prostate biopsy with or without antibiotic prophylaxis
As described above.
|
Outcome Measures
Primary Outcome Measures
- Incidence of sepsis [Up to 30 days]
Post biopsy sepsis will be defined by SIRS criteria
- Incidence of post biopsy urinary tract infection [Up to 30 days]
Post biopsy urinary tract infection not demanding hospital admission within 30
Other Outcome Measures
- Pain during the local anesthesia application [Immediately after the intervention]
Patients will be asked to mention the intensity of pain during the anesthesia using Visual Analog Score for pain, range: 0 to 10, the worse is 10.
- Pain during the prostate biopsy [Immediately after the intervention]
Patients will be asked to mention the intensity of pain during the prostate biopsy using Visual Analog Score for pain, range: 0 to 10, the worse is 10.
Eligibility Criteria
Criteria
Inclusion Criteria: Clinical indication for prostate cancer
-
Exclusion Criteria:
-
Patients with symptoms of urinary tract infection or positive findings on urine dipstic before biopsy
-
Patients with indwelling urethral catheter
-
Patients with immunodeficiency disorders
-
Patients with high risk for infective endocarditis [European Society of Cardiology]
-
Patients with a prosthetic aortic or pulmonary valve
-
Patients with previous infective endocarditis
-
Patients with congenital heart disease who are cyanotic and those who have had palliative shunts/conduits/other prostheses
-
Patients with a history of thromboembolic disease
-
Patients with a history of allergy to the study drug
-
Patients who do not wish to participate in the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Vivantes Klinikum am Urban | Berlin | Germany | ||
| 2 | Oslo University Hospital, Aker | Oslo | Norway | 0514 |
Sponsors and Collaborators
- Oslo University Hospital
- University of Oslo
Investigators
- Principal Investigator: Eduard Baco, MD, PhD, Oslo University Hospital, Oslo, Norway
- Study Chair: Erik Rud, MD,PhD, Oslo University Hospital, Oslo, Norway
- Study Chair: Karsten Gunzel, MD, Vivantes Klinkum Am Urban, Berlin, Germany
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2019/1266